Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion
Marksans Pharma Ltd · Financial Result · 04 Nov 2026, 7:05 pm
Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 million for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 million and 11.8% QoQ. Consolidated net profit attributable to owners rose 43.8% YoY to ₹1,413.12 million (₹982.50 million in Q2 FY26), with basic EPS improving to ₹3.12 from ₹2.17. For H1 FY27, operating revenue reached ₹17,809.65 million with PAT at ₹2,984.79 million. Inorganic European expansion continued via 100% acquisitions of Netherlands-based QliniQ B.V. (€7.50 million) and Germany-based ABCnow GmbH (€1.10 million).
Original exchange filing (PDF)
More announcements from Marksans Pharma Ltd
- Transcript of Investors/Analyst meet on Q2 FY27 Financial Results · 13 Nov 2026
- Audio Recording of investor(s)/analyst(s) meet Conference Call on Q2 FY 27 Financial Results · 05 Nov 2026
- Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024 · 04 Nov 2026
- Press Release for Financial Results Q2FY27 · 04 Nov 2026
- Investor Presentation Q2FY27 · 04 Nov 2026
- Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Please find attached outcome of the Board meeting held on 04 November 2026 · 04 Nov 2026
- Intimation of schedule for Q2FY27 Earnings Conference Call · 05 Nov 2026
